Sarepta Therapeutics, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Sarepta Therapeutics (SRPT).

If you purchased or held Sarepta Therapeutics securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Sarepta Therapeutics

Sarepta positions itself as a leader in precision genetic medicine. Its flagship product, Elevidys, is a gene therapy approved for certain patients with Duchenne muscular dystrophy (DMD).

The commercial rollout was rapid. By the fourth quarter of 2024 Elevidys generated $384 million in revenue, a 112 percent sequential increase, and management said the therapy had already sold more than $1 billion since approval.

Looking ahead, the company told investors it was projecting 2025 Elevidys sales of $2.9 billion to $3.1 billion.

The Allegations

• Safety disclosures and stock collapses
• On March 18 2025 Sarepta announced the first Elevidys-related death, and the stock fell approximately 25 percent.
• A second death was revealed on June 16 2025, after which shares plummeted more than 42 percent in a single day.
• Following the second fatality, Sarepta paused shipments of Elevidys for non-ambulatory patients and announced tighter safety protocols.
• On June 24 2025 Reuters reported that the FDA opened an investigation into two Elevidys-related cases of acute liver failure or death.

• Allegedly misleading safety statements
• In an October 30 2023 press release announcing EMBARK study results, Sarepta asserted that “no new safety signals were observed”.
• Even after the first death, CEO Doug Ingram said on May 7 2025 that Elevidys had “one of the most impressive safety profiles” among gene therapies.
• Reuters later noted that a pivotal Elevidys trial failed to meet its primary endpoint.

• Efficacy and benefit claims
• On August 7 2024 Ingram cited “a wealth of compelling clinical evidence” supporting FDA approval.
• The Financial Times reported that Sarepta said Elevidys “significantly improves patients’ quality of life”.

• Omitted risk information: Reuters noted that Elevidys’ U.S. label mentioned acute liver injury but did not disclose a potential risk of death.
• Insider trading red flag: CFO Claude Nicaise sold 2,491 shares at $99.64 each on March 13 2025, just days before the first death was disclosed.

Your Rights and Next Steps

Investors who bought or held Sarepta shares during the period in which the alleged misstatements and omissions occurred may have legal claims.

Lawyers are ready to help investors determine whether their trades qualify, calculate potential losses and, if appropriate, seek appointment as a lead plaintiff in a future class action. Taking part in the investigation involves no cost or obligation.

You May Be Entitled to Compensation

If you experienced losses in Sarepta Therapeutics stock, act now. Complete the form below to connect with the investigation team and preserve your potential recovery.

Time limits apply, so prompt action is important to protect your rights.